A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor
Launched by SERA PROGNOSTICS, INC. · May 25, 2016
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Subject is 18 years of age or older
- • Subject has singleton gestation
- • Subject is able to provide consent
- • Gestational age is confirmed by a documented crown rump length on an ultrasound performed at the study site within 6 0/7 weeks and 13 6/7 weeks gestation (first trimester)
- • Subject has no signs and/or symptoms of preterm labor and has intact membranes
- • Investigator believes subject is willing to comply with study visits and procedures
- • Investigator believes the subject's delivery data will be available within 15 business days from delivery, and neonatal data will be available for data collection purposes within 15 business days from discharge
- Exclusion Criteria:
- • The subject has a planned cesarean section or induction of labor prior to 370/7 weeks of gestation
- • The subject has a planned cerclage placement for the current pregnancy
- • There is a known or suspected fetal anomaly or chromosomal abnormality
- • The subject has had a blood transfusion during the current pregnancy
- • The subject has known elevated bilirubin levels (hyperbilirubinemia)
- * The subject has taken or plans to take any of the following medications during the current pregnancy:
- • Progesterone or progesterone-derivative medication after 13 6/7 weeks gestation
- • Enoxaparin, heparin, heparin sodium, low molecular weight heparin after first day of last menstrual period
- • The subject has participated in, or plans to participate in, an interventional treatment study during the current pregnancy
- • The current pregnancy was previously a multiple gestation that is now a single fetus due to reduction, vanishing twin, etc.
Trial Officials
Durlin E Hickok, MD
Study Chair
Sera Prognostics
About Sera Prognostics, Inc.
Sera Prognostics, Inc. is a leading biotechnology company dedicated to advancing women's health through innovative diagnostic solutions. With a focus on developing predictive tests for pregnancy-related complications, the company harnesses cutting-edge technology and extensive clinical research to improve maternal and neonatal outcomes. Sera Prognostics is committed to delivering actionable insights that empower healthcare providers and patients, ultimately enhancing the quality of care in obstetrics. By prioritizing scientific rigor and collaboration, the company aims to transform prenatal care and support healthier pregnancies worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Orange, California, United States
Charleston, South Carolina, United States
Springfield, Massachusetts, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Galveston, Texas, United States
Philadelphia, Pennsylvania, United States
Chapel Hill, North Carolina, United States
Galveston, Texas, United States
Indianapolis, Indiana, United States
Portland, Oregon, United States
Denver, Colorado, United States
New Orleans, Louisiana, United States
Aurora, Colorado, United States
Greenville, South Carolina, United States
Phoenix, Arizona, United States
San Diego, California, United States
Chattanooga, Tennessee, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials